Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice

Katia Scotlandi, Stefania Benini, Patrizia Nanni, Pier Luigi Lollini, Giordano Nicoletti, Lorena Landuzzi, Massimo Serra, Maria Cristina Manara, Piero Picci, Nicola Baldini

Research output: Contribution to journalArticlepeer-review


Innovative, more effective treatment modalities are needed for Ewing's sarcoma (ES), a neoplasm with a disappointingly low survival rate despite the use of aggressive multimodal therapeutic approaches. We have previously shown (K. Scotlandi et al., Cancer Res., 56: 4570-4574, 1996) the existence and the pathogenetic relevance of an autocrine loop that is mediated by the insulin- like growth factor-I receptor (IGF-IR) and is crucial for the survival and proliferation of ES cells in vitro. In this study, we report that the IGF- IR-blocking monoclonal antibody αIR3 may also significantly inhibit ES cell growth in vivo. In particular, in almost one-half of the animals tested, after s.c. inoculation with TC-71 ES cells, the blockage of IGF-IR by αIR3 induced a complete regression of tumors that developed, which suggests that IGF-IR is valuable as a specific target for novel therapeutic strategies. In addition, suramin, a drug that can interfere with growth factor binding with their receptors, inhibited the tumorigenic and the metastatic ability of TC- 71 cells and, therefore, is a promising agent to be combined with conventional cytotoxic drugs for the design of more effective therapeutic regimens.

Original languageEnglish
Pages (from-to)4127-4131
Number of pages5
JournalCancer Research
Issue number18
Publication statusPublished - Sep 15 1998

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice'. Together they form a unique fingerprint.

Cite this